Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-005 · synthetic case LIVER-FX-09
Alcohol-related liver disease predominant
About 90 g a day in a man with steatosis.
Purpose: About 90 g a day in a man with steatosis.
Inputs the engine received
Liver tests and imaging
- Hepatic steatosis documented
- Yes
- AST
- 80 U/L
- ALT
- 52 U/L
- Platelets
- 170 ×10⁹/L
Patient
- Age
- 49 years
- Sex
- Male
- Alcohol intake
- 90 g/day
Cardiometabolic criteria
- BMI
- 27 kg/m²
Other liver disease and context
- Hepatitis B and C testing already done
- Yes
What the engine reports
A high-risk non-invasive result (or known cirrhosis) needs specialist evaluation. Confirmation of stage belongs to hepatology.
Detected clinical pattern
Alcohol-Related Liver Disease Predominant
Alcohol intake is above the MetALD range. The pattern is classified as alcohol-related liver disease.
- Alcohol: Alcohol 90 g/day · ALD range
- Fibrosis risk: Fibrosis risk · high
Calculations
- FIB-4
- 3.2
Lower cutoff 1.3; high above 2.67.
Recommended next steps
For physician consideration. Urgent review always comes first.
- 1Consider referral to hepatology.AASLD 2023.
Evidence and rule trace · 6 rules
LV-ALC-01Alcohol intake category
Inputs: alcohol 90 g/day (male)
Alcohol-related liver disease predominant.
LV-04ALT above the AASLD upper limit
Inputs: ALT 52 U/L (limit 33 for male)
ALT above the sex-specific upper limit.
LV-REF-01Hepatology referral to consider
Inputs: advanced fibrosis likely
Referral to hepatology is reasonable to consider.
Evidence
- EV-AASLD-2023 · Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
- EV-DELPHI-2023 · Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986.
- EV-MCPHERSON-2017 · McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740-751.
Physician adjudication required. Clinical decision support for physician review. This output classifies steatotic liver disease under the 2023 nomenclature and stratifies fibrosis risk. It does not stage fibrosis by itself, diagnose a cause, or recommend a drug. Physician adjudication is required.
Change the values
The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.
Fibrosis risk by non-invasive tests
✓ Low
FIB-4 <1.3 (<2.0 from 65), stiffness <8 kPa
✓ Indeterminate
Needs a second-line test
● High
FIB-4 >2.67, stiffness ≥12 kPa or ELF ≥9.8
Liver tests and imaging
Patient
A standard US drink is about 14 g.
Cardiometabolic criteria
Other liver disease and context
Cirrhosis, decompensation and trends
More liver cases
LIVER-FX-01
Steatosis with metabolic risk and a low FIB-4
A 52-year-old man with fatty liver on ultrasound, BMI 31 and triglycerides 190.
LIVER-FX-02
Type 2 diabetes, no imaging yet
A 58-year-old with diabetes and normal enzymes: the screening question.
LIVER-FX-03
Indeterminate FIB-4
FIB-4 of 2.0 in a 56-year-old with steatosis.
LIVER-FX-04
High FIB-4
FIB-4 above 5 in a 63-year-old man with low platelets.
LIVER-FX-05
FIB-4 of 1.65 at age 70
Low risk under the age-adjusted cutoff of 2.0.
LIVER-FX-06
Stiffness 14 kPa with a low FIB-4
Discordant tests: the elastography result prevails as a warning.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.